Leucovorin vs Levoleucovorin — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Folate Analog

Leucovorin

Brand: VYKOURA

First FDA approval: 1987-09-14

Folate Analog

Levoleucovorin

Brand: KHAPZORY

First FDA approval: 2016-07-07

Lowest NADACAcquisition cost floor across all NDCs

$0.431Per unit

—Per unit

Average NADACAcross all dosage forms and strengths

$1.65Up to $2.38

—

Generic manufacturersActive ANDA holders — FDA Orange Book

1145 total ANDAs filed

57 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$7.4MFull year

$8605Full year

Part D claims (CY24)Total fills, all strengths

158K52K beneficiaries

29— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$47Per claim, all NDCs

$297Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

—Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

—None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes11 manufacturers

Yes5 manufacturers